Barclays’s MiNK Therapeutics INKT Stock Holding History

Barclays’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4	Closed	-$45	–	5233
2025 Q4	$45	Buy	+4	New	+$52	﹤0.01%	5134
2022 Q2	–	Sell	-33	Closed	-$1K	–	5142
2022 Q1	$1K	Buy	+33	New	+$991	﹤0.01%	4840

Other funds holding INKT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Paladin Partners Hartland, Wisconsin $139M AUM

AGWCA

Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Barclays's INKT Position: Q1 2026 in Review

Barclays sold out of MiNK Therapeutics (INKT) in Q1 2026, closing a stake of 4 shares — an estimated $45 sold.

Barclays first reported a position in INKT in Q1 2022 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

Barclays reported no remaining MiNK Therapeutics position as of Q1 2026 after selling out during the quarter.
Barclays sold 4 MiNK Therapeutics shares in Q1 2026, an estimated $45.
Barclays first reported a position in MiNK Therapeutics in Q1 2022 and held it in 2 quarters.
Barclays's MiNK Therapeutics position peaked at $1K in Q1 2022.
23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.